Well, I reckon the whole market will IMHO want to buy this come its time back on the market. $28 is ridiculously low. I need to scrounge some cash for a few more buy orders as they might pay dividends as for me, another suitor is bound to come in.
It is too weak an TO bid offer 4 Bayer and/or Amgen and/ or BTG and/ or Merck not to come in and have a go.
At BTG, Dame Makin would not be worried about Varian as a competitor but may be worried that Bayer and/or Amgen and/ or Astra Zeneca and/ or Merck will come into the liver cancer space.
IMHO this is not over yet by a long shot. This Board by recommending it are a bit chicken livered and need a clean (a nice warm bath and retraining in governance, risk and compliance).
Has to be worth $35 - $40 IMHO based on fundamentals. Some instos as well as traders will go nuts on the buyside come its trading.
Another suitor must be imminent do u not reckon? Otherwise this is a shocking indictment of the sharemarket, scandalous?
Ann: Trading Halt, page-40
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.8¢ | 17.5¢ | $51.74K | 295.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2529419 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 2426769 | 38 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| SRX (ASX) Chart |